# Kopra Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kopra-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.kopra.bio/
- Latest round: Seed (Sep 11, 2024)
- Investors on record: 1

## About

Based in California, US, and founded in 2024 by co-founders Alexander Haddad and Andrew Bartynski (CEO), Kopra Bio operates as a provider of cancer immunotherapy that transforms cancer cells into biofactories producing their own destruction for oncologists and medical researchers. In September 2024, Kopra Bio raised an undisclosed amount of seed funding from Pioneer Fund.

The company provides a wide range of biotechnology solutions, such as cancer immunotherapies intended to transform cancer cells into biofactories that self-destruct. Moreover, the firm's offerings include bioengineering solutions, advanced research platforms, and advanced therapies aimed at targeting and treating cancer more effectively. Kopra Bio also offers services like collaborative research opportunities, clinical trial support, and data analysis for oncology professionals and research institutions. The company’s work is focused on advancing cancer treatment by using advanced, science-driven approaches in immunotherapy and bioengineering.

## Funding rounds

- Seed, Sep 11, 2024 — Pioneer Fund

## Investors

- Pioneer Fund (https://capitalatlas.ai/funds/pioneer-fund) — Seed